Retinopathy of PrematurityNCT04767178
Pain Management During Screening for Retinopathy of Prematurity
An observational study of Retinopathy of Prematurity and Pain Management, run by Istanbul Medeniyet University at 1 site in Turkey (Türkiye).
Trial summary
Abstract Background: Screening examinations for retinopathy of prematurity (ROP) is critical to reduce ROP-related vision loss, however, the procedure is painful and uncomfortable, and topical anesthetics do not completely suppress the painful responses. Read more about this study
- Who is it for?
- Ages 22 to 33 weeks
- Conditions the study is for
- Retinopathy of Prematurity, Pain Management
- What is being tested?
- Ibuprofen (Sanofi, Istanbul, Turkey) and Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
- Type of treatment
- Pill or oral medicine
- How many people
- 44 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2020to 15 Aug 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 33 weeks
- All sexes
- No healthy volunteers
- Child
Study population: The present study enrolled preterm infants with a gestational age of ≤32 weeks or birth weight ≤ 1500 g who were screened for ROP.
Who may be able to join
- Preterm infants of ≤32 weeks of gestational
- Preterm infants ≤ 1500 gram of birth weight
Who cannot join
- Major congenital abnormalities
- Neurological dysfunction
- Infants who were mechanically ventilated and/or sedated, hemodynamically unstable
- Infants > 32 weeks of gestational
- The infants whose parents denied consent were also not included.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Oral Ibuprofen Versus Oral Paracetamol in Pain Management During Screening for Retinopathy of Prematurity: A Prospective Observational Study
Abstract Background: Screening examinations for retinopathy of prematurity (ROP) is critical to reduce ROP-related vision loss, however, the procedure is painful and uncomfortable, and topical anesthetics do not completely suppress the painful responses. The number of safe and effective pharmacological options to reduce pain during eye examinations for ROP screening in preterm infants is limited.
Objective: This study compared the efficacy of oral ibuprofen and oral paracetamol in reducing pain during screening for ROP in preterm infants.
Design: This prospective observational study was conducted at a tertiary-care neonatal intensive care units. Forty-four preterm infants with gestational age ≤ 32 weeks undergoing ROP screening were included. Each enrolled infant received either oral ibuprofen 10 mg/kg (n = 22) or oral paracetamol 10 mg/kg (n = 22) one hour before eye examination. The primary outcome measure was pain assessed by the Neonatal Pain, Agitation, and Sedation (N-PASS) scale. Secondary outcome measures were tachycardia, bradycardia, desaturations, and crying time.
Read the detailed description
Retinopathy of prematurity (ROP) is a physiopathological condition that develops upon abnormal proliferation of the retinal veins in neonates, and its pathogenesis is unknown.1 With the advancements in neonate care, the survival rate of premature babies with extremely low gestational ages and birth weights has increased significantly; however, this has also resulted in an increasing incidence of ROP, which may lead to vision defects and/or blindness. Early diagnosis, and timely and effective treatment may prevent vision loss and thus improve the developmental process and the quality of life of these infants. Therefore, recurring screening with retinal examination is essential to identify neonates who need ROP treatment.2, 3 The American Academy of Pediatrics and American Academy of Ophthalmology recommend ROP screening for preterm infants with a birth weight of ≤1500 g or a gestational age of ≤30 weeks, and selected infants with a birth weight between 1500 and 2000 g or a gestational age of >30 weeks who have received cardiopulmonary supportive therapy, or who are considered by the attending clinician to be at risk for the development of ROP.4 The ophthalmological examinations for screening ROP involve repeated use of mydriatic eye drops, physical constriction, forced opening of the eyelids, insertion of the blepharostat, scleral indentation, and dense light, all of which cause pain and stress to the infant.5, 6 The extreme and long-term unreduced pain resulting from the interventions applied in the neonatal intensive care units (NICU) may generally cause life-threatening effects in organs and systems. Inadequate management of pain in preterm neonates can cause physiological changes and may also obscure the behavior of the infant, interactions between the family and the infant, and the adaptation of the infant to the social world, causing neurological and behavioral disorders and negatively affecting growth.7, 8, 9, 10 Thus, determination of optimal strategies for stress reduction and pain management related to these medical procedures is important in order to minimize the discomfort experienced by these neonates.
In order to reduce the pain and stress related to ROP examination, non-pharmacological methods, including the use of pacifiers, skin-to-skin touch, swaddling, kangaroo care, positioning, musical therapy, breast milk and breast feeding, single or recurring doses of oral sucrose, and personalized developmental care applications, have been used.5, 11, 12, 13, 14 However, a recent meta-analysis of randomized controlled studies evaluated a variety of non-pharmacological pain-reducing interventions in addition to topical ophthalmic anesthetics for ROP examination. Although multisensory pain treatments (e.g., oral dextrose/sucrose solution, breast milk, swinging, singing, non-feeding suction, swaddling) may reduce the pain to varying degrees, no specific treatment has been reported to show significant pain-relief ability. The Premature Infant Pain Profile (PIPP) score in most of the studies was >12.11 Pharmacological methods are used for pain relief as well as non-pharmacological in neonates. The pharmacological agents include local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), and opioid medications.15 Although topical anesthetics are routinely used in ROP examination in the NICU, they do not offer complete relief from pain.12 Moreover, opioid analgesics should be used carefully, due to their adverse effects such as respiratory depression, apnea, bradycardia, hypotension, intestinal hypoperistalsis, and bladder dysfunction. 16 NSAIDs are commonly used in newborns and children as antipyretic agents to control fever and as analgesic, anti-inflammatory, and vasoactive agents to manage pain and modulate inflammation.17 Paracetamol shows analgesic and antipyretic effects by inhibiting the cyclooxygenase (COX)-2 enzyme.17 It can be used safely in neonates during mild to moderately painful procedures and in the postoperative period. Malnory et al. showed that the preoperative use of paracetamol during circumcision of late preterm and term infants reduced pain within the first 24 h.18 Ceelie et al. reported that the intravenous use of paracetamol in neonates and infants after major surgeries reduced the need for morphine in the first 48 h following surgery.19 Ibuprofen, another NSAID, inhibits COX-1 and COX-2 enzymes to show analgesic, antipyretic, and anti-inflammatory effects.17 However, the role of ibuprofen in reducing pain in neonates has not been studied in detail. Recently, these two medications are commonly used in NICUs for ductus closure.20 To our knowledge, no previous study has compared the pain-reducing effect of ibuprofen and paracetamol in preterm infants during ROP examinations. Thus, this study aimed to compare the pain-reducing effects of single-dose ibuprofen and paracetamol in preterm infants during ROP examination by using the Neonatal Pain, Agitation, and Sedation (N-PASS) scale.
- Conditions
- Retinopathy of Prematurity, Pain Management
- Being tested
- Ibuprofen (Sanofi, Istanbul, Turkey), Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
- Keywords
- Analgesia, ibuprofen, N-PASS, pain management, paracetamol, preterm infant, retinopathy of prematurity
- Medical subject headings
- Retinopathy of Prematurity, Agnosia, Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ibuprofen (Sanofi, Istanbul, Turkey)Drug
Also called Dolven
Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Paracetamol (GlaxoSmithKline, Istanbul, Turkey)Drug
Also called Parol
Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
| Study group | Role | What they receive |
|---|---|---|
| Ibuprofen group | Infants that received oral ibuprofen were categorized into the ibuprofen group Receives: Drug: Ibuprofen (Sanofi, Istanbul, Turkey) | |
| Paracetamol group | Infants that received oral paracetamol were categorized into the paracetamol group Receives: Drug: Paracetamol (GlaxoSmithKline, Istanbul, Turkey) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Neonatal Pain, Agitation, and Sedation scale
The mean of the Neonatal Pain, Agitation, and Sedation score (A score >+3 indicates pain)
Measured: 8 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2021
- Study start1 Jan 2020
- Primary completion30 Jul 2020
- Study completion15 Aug 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Retinopathy of PrematurityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Medeniyet University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ozgul Bulut, Istanbul Medeniyet University
- Investigators
- Ozgul Bulut, Principal investigator, Medeniyet University Göztepe Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04767178
- Sponsor's protocol ID
- Ozgul1
- Status last verified
- Feb 2021
- First submitted
- 14 Feb 2021
- Last updated
- 23 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Bulut O, Tarak Bozkurt O, Arslanoglu S. Oral Ibuprofen Versus Oral Paracetamol in Pain Management During Screening for Retinopathy of Prematurity: A Prospective Observational Study. J Perinat Neonatal Nurs. 2022 Jul-Sep 01;36(3):305-311. doi: 10.1097/JPN.0000000000000675.
PubMed 35894729
Study at a glance
From the registry record, last updated by the sponsor on 23 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oral Ibuprofen Versus Oral Paracetamol in Pain Management During Screening for Retinopathy of Prematurity: A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT04767178
- Acronym / sponsor ID
- Ozgul1
- Conditions
- Retinopathy of Prematurity, Pain Management
- Keywords
- Analgesia, ibuprofen, N-PASS, pain management, paracetamol, preterm infant, retinopathy of prematurity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Istanbul Medeniyet UniversityUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 30 Jul 2020 (actual)
- Study completion
- 15 Aug 2020 (actual)
- First posted
- 23 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Abstract Background: Screening examinations for retinopathy of prematurity (ROP) is critical to reduce ROP-related vision loss, however, the procedure is painful and uncomfortable, and topical anesthetics do not completely suppress the painful responses. The number of safe and effective pharmacological options to reduce pain during eye examinations for ROP screening in preterm infants is limited.
Objective: This study compared the efficacy of oral ibuprofen and oral paracetamol in reducing pain during screening for ROP in preterm infants.
Design: This prospective observational study was conducted at a tertiary-care neonatal intensive care units. Forty-four preterm infants with gestational age ≤ 32 weeks undergoing ROP screening were included. Each enrolled infant received either oral ibuprofen 10 mg/kg (n = 22) or oral paracetamol 10 mg/kg (n = 22) one hour before eye examination. The primary outcome measure was pain assessed by the Neonatal Pain, Agitation, and Sedation (N-PASS) scale. Secondary outcome measures were tachycardia, bradycardia, desaturations, and crying time.
Detailed description
Retinopathy of prematurity (ROP) is a physiopathological condition that develops upon abnormal proliferation of the retinal veins in neonates, and its pathogenesis is unknown.1 With the advancements in neonate care, the survival rate of premature babies with extremely low gestational ages and birth weights has increased significantly; however, this has also resulted in an increasing incidence of ROP, which may lead to vision defects and/or blindness. Early diagnosis, and timely and effective treatment may prevent vision loss and thus improve the developmental process and the quality of life of these infants. Therefore, recurring screening with retinal examination is essential to identify neonates who need ROP treatment.2, 3 The American Academy of Pediatrics and American Academy of Ophthalmology recommend ROP screening for preterm infants with a birth weight of ≤1500 g or a gestational age of ≤30 weeks, and selected infants with a birth weight between 1500 and 2000 g or a gestational age of >30 weeks who have received cardiopulmonary supportive therapy, or who are considered by the attending clinician to be at risk for the development of ROP.4 The ophthalmological examinations for screening ROP involve repeated use of mydriatic eye drops, physical constriction, forced opening of the eyelids, insertion of the blepharostat, scleral indentation, and dense light, all of which cause pain and stress to the infant.5, 6 The extreme and long-term unreduced pain resulting from the interventions applied in the neonatal intensive care units (NICU) may generally cause life-threatening effects in organs and systems. Inadequate management of pain in preterm neonates can cause physiological changes and may also obscure the behavior of the infant, interactions between the family and the infant, and the adaptation of the infant to the social world, causing neurological and behavioral disorders and negatively affecting growth.7, 8, 9, 10 Thus, determination of optimal strategies for stress reduction and pain management related to these medical procedures is important in order to minimize the discomfort experienced by these neonates.
In order to reduce the pain and stress related to ROP examination, non-pharmacological methods, including the use of pacifiers, skin-to-skin touch, swaddling, kangaroo care, positioning, musical therapy, breast milk and breast feeding, single or recurring doses of oral sucrose, and personalized developmental care applications, have been used.5, 11, 12, 13, 14 However, a recent meta-analysis of randomized controlled studies evaluated a variety of non-pharmacological pain-reducing interventions in addition to topical ophthalmic anesthetics for ROP examination. Although multisensory pain treatments (e.g., oral dextrose/sucrose solution, breast milk, swinging, singing, non-feeding suction, swaddling) may reduce the pain to varying degrees, no specific treatment has been reported to show significant pain-relief ability. The Premature Infant Pain Profile (PIPP) score in most of the studies was >12.11 Pharmacological methods are used for pain relief as well as non-pharmacological in neonates. The pharmacological agents include local anesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), and opioid medications.15 Although topical anesthetics are routinely used in ROP examination in the NICU, they do not offer complete relief from pain.12 Moreover, opioid analgesics should be used carefully, due to their adverse effects such as respiratory depression, apnea, bradycardia, hypotension, intestinal hypoperistalsis, and bladder dysfunction. 16 NSAIDs are commonly used in newborns and children as antipyretic agents to control fever and as analgesic, anti-inflammatory, and vasoactive agents to manage pain and modulate inflammation.17 Paracetamol shows analgesic and antipyretic effects by inhibiting the cyclooxygenase (COX)-2 enzyme.17 It can be used safely in neonates during mild to moderately painful procedures and in the postoperative period. Malnory et al. showed that the preoperative use of paracetamol during circumcision of late preterm and term infants reduced pain within the first 24 h.18 Ceelie et al. reported that the intravenous use of paracetamol in neonates and infants after major surgeries reduced the need for morphine in the first 48 h following surgery.19 Ibuprofen, another NSAID, inhibits COX-1 and COX-2 enzymes to show analgesic, antipyretic, and anti-inflammatory effects.17 However, the role of ibuprofen in reducing pain in neonates has not been studied in detail. Recently, these two medications are commonly used in NICUs for ductus closure.20 To our knowledge, no previous study has compared the pain-reducing effect of ibuprofen and paracetamol in preterm infants during ROP examinations. Thus, this study aimed to compare the pain-reducing effects of single-dose ibuprofen and paracetamol in preterm infants during ROP examination by using the Neonatal Pain, Agitation, and Sedation (N-PASS) scale.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ibuprofen group | – | Drug: Ibuprofen (Sanofi, Istanbul, Turkey)Infants that received oral ibuprofen were categorized into the ibuprofen group |
| Paracetamol group | – | Drug: Paracetamol (GlaxoSmithKline, Istanbul, Turkey)Infants that received oral paracetamol were categorized into the paracetamol group |
Who may qualify
- Ages
- 22 to 33 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- The present study enrolled preterm infants with a gestational age of ≤32 weeks or birth weight ≤ 1500 g who were screened for ROP.
Key inclusion criteria (2 listed)
- Preterm infants of ≤32 weeks of gestational
- Preterm infants ≤ 1500 gram of birth weight
Key exclusion criteria (5 listed)
- Major congenital abnormalities
- Neurological dysfunction
- Infants who were mechanically ventilated and/or sedated, hemodynamically unstable
- Infants > 32 weeks of gestational
- The infants whose parents denied consent were also not included.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ibuprofen (Sanofi, Istanbul, Turkey)Also: DolvenEach enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination. | Drug | Ibuprofen group |
| Paracetamol (GlaxoSmithKline, Istanbul, Turkey)Also: ParolEach enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination. | Drug | Paracetamol group |
Primary outcome
The Neonatal Pain, Agitation, and Sedation scale
Time frame: 8 month
The mean of the Neonatal Pain, Agitation, and Sedation score (A score >+3 indicates pain)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Feb 2021.
- Derived from this study: PubMed 35894729Bulut O, Tarak Bozkurt O, Arslanoglu S. Oral Ibuprofen Versus Oral Paracetamol in Pain Management During Screening for Retinopathy of Prematurity: A Prospective Observational Study. J Perinat Neonatal Nurs. 2022 Jul-Sep 01;36(3):305-311. doi: 10.1097/JPN.0000000000000675.
- Individual participant dataSharing planned: No
Related trials for Retinopathy of Prematurity
RecruitingObservational study
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Retinopathy of Prematurity, Preterm Infants
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
RecruitingObservational study
Imaging Retinal Vasculature in Infant Eyes
Retinopathy of Prematurity
RecruitingPhase 1
Safety, PK and PD of FLQ-101 in Premature Neonates
Retinopathy of Prematurity (ROP)
Recruiting
Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care
Retinopathy of Prematurity (ROP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ozgul Bulut principal investigator
Medeniyet University Göztepe Training and Research Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinopathy of Prematurity and Pain Management, run by Istanbul Medeniyet University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Neonatal Pain, Agitation, and Sedation scale (time frame: 8 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04767178, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2021; AzTrials last refreshed its copy on 7 Nov 2026.